Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Double-Blind, Randomized, Phase III Study of CS1001 in Combination With CAPOX Chemotherapy Compared to Placebo in Combination With CAPOX Chemotherapy in Subjects With Unresectable Locally Advanced or Metastatic GC or GEJ Adenocarcinoma

Next Previous
Trial Profile

A Multi-Center, Double-Blind, Randomized, Phase III Study of CS1001 in Combination With CAPOX Chemotherapy Compared to Placebo in Combination With CAPOX Chemotherapy in Subjects With Unresectable Locally Advanced or Metastatic GC or GEJ Adenocarcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sugemalimab (Primary) ; Capecitabine; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms GEMSTONE-303
  • Sponsors CStone Pharmaceuticals

Most Recent Events

  • 25 Feb 2025 Results presented in the CStone Pharmaceuticals Media Release.
  • 24 Feb 2025 According to a CStone Pharmaceuticals media release, company announced the publication of the GEMSTONE-303 study results for sugemalimab (brand name: Cejemly) in the prestigious Journal of the American Medical Association (JAMA).
  • 26 Jul 2024 According to a CStone Pharmaceuticals media release, company is preparing to submit Marketing Authorization Application for first-line Gastric Cancer indication.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top